PDS Biotechnology (NASDAQ:PDSB) Issues Earnings Results

PDS Biotechnology (NASDAQ:PDSB) released its quarterly earnings results on Wednesday. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02, FiscalAI reports.

Here are the key takeaways from PDS Biotechnology’s conference call:

• PDS Biotechnology amended VERSATILE-003 to use progression-free survival as an interim primary endpoint, which management believes could speed an accelerated approval path and shorten the trial’s duration.
• The company said the amended design also reduces costs by lowering the trial size from about 350 patients to 250 and changing the randomization ratio to 1:1:1.
• Management highlighted continued momentum in PDS0101, saying the therapy remains a differentiated late-stage option in HPV-16 positive head and neck cancer because it is subcutaneous and requires only five doses.
• The company reported encouraging updates from its PDS01ADC program in both colorectal and prostate cancer, including published biomarker data and early clinical results that support broader immuno-oncology potential.
• First-quarter 2026 results showed a net loss of $7.3 million versus $8.5 million a year ago, with cash of $21.7 million at quarter-end and lower operating expenses year over year.

PDS Biotechnology Stock Performance

Shares of PDSB stock traded up $0.16 during mid-day trading on Thursday, hitting $1.49. 1,787,037 shares of the stock were exchanged, compared to its average volume of 786,263. The stock’s fifty day simple moving average is $0.88 and its two-hundred day simple moving average is $0.86. The stock has a market capitalization of $80.79 million, a price-to-earnings ratio of -1.97 and a beta of 1.51. PDS Biotechnology has a 12-month low of $0.51 and a 12-month high of $1.92. The company has a debt-to-equity ratio of 1.27, a quick ratio of 2.98 and a current ratio of 2.98.

Hedge Funds Weigh In On PDS Biotechnology

Several hedge funds have recently made changes to their positions in PDSB. Armistice Capital LLC purchased a new position in shares of PDS Biotechnology during the fourth quarter worth about $2,182,000. Squarepoint Ops LLC grew its holdings in shares of PDS Biotechnology by 116.1% during the third quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock worth $295,000 after buying an additional 156,662 shares during the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of PDS Biotechnology by 117.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock worth $151,000 after buying an additional 106,300 shares during the last quarter. Susquehanna International Group LLP grew its holdings in shares of PDS Biotechnology by 603.7% during the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock worth $95,000 after buying an additional 80,937 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of PDS Biotechnology during the second quarter worth about $92,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on PDSB shares. Wall Street Zen upgraded PDS Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Weiss Ratings restated a “sell (e+)” rating on shares of PDS Biotechnology in a research note on Tuesday, April 21st. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of PDS Biotechnology in a research note on Wednesday, April 15th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, PDS Biotechnology has a consensus rating of “Hold” and a consensus price target of $9.00.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.